PTGX
Price
$56.89
Change
-$0.59 (-1.03%)
Updated
Aug 25, 04:59 PM (EDT)
Capitalization
3.54B
72 days until earnings call
TNXP
Price
$34.51
Change
-$3.47 (-9.14%)
Updated
Aug 25, 04:59 PM (EDT)
Capitalization
303.21M
77 days until earnings call
Interact to see
Advertisement

PTGX vs TNXP

Header iconPTGX vs TNXP Comparison
Open Charts PTGX vs TNXPBanner chart's image
Protagonist Therapeutics
Price$56.89
Change-$0.59 (-1.03%)
Volume$4.98K
Capitalization3.54B
Tonix Pharmaceuticals Holding
Price$34.51
Change-$3.47 (-9.14%)
Volume$8.83K
Capitalization303.21M
PTGX vs TNXP Comparison Chart in %
Loading...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TNXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTGX vs. TNXP commentary
Aug 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTGX is a StrongBuy and TNXP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 26, 2025
Stock price -- (PTGX: $57.48 vs. TNXP: $37.98)
Brand notoriety: PTGX and TNXP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTGX: 64% vs. TNXP: 117%
Market capitalization -- PTGX: $3.54B vs. TNXP: $303.21M
PTGX [@Biotechnology] is valued at $3.54B. TNXP’s [@Biotechnology] market capitalization is $303.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $99.72B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTGX’s FA Score shows that 1 FA rating(s) are green whileTNXP’s FA Score has 1 green FA rating(s).

  • PTGX’s FA Score: 1 green, 4 red.
  • TNXP’s FA Score: 1 green, 4 red.
According to our system of comparison, PTGX is a better buy in the long-term than TNXP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTGX’s TA Score shows that 7 TA indicator(s) are bullish while TNXP’s TA Score has 3 bullish TA indicator(s).

  • PTGX’s TA Score: 7 bullish, 2 bearish.
  • TNXP’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, PTGX is a better buy in the short-term than TNXP.

Price Growth

PTGX (@Biotechnology) experienced а +2.51% price change this week, while TNXP (@Biotechnology) price change was -26.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was +18.77%, and the average quarterly price growth was +29.32%.

Reported Earning Dates

PTGX is expected to report earnings on Nov 05, 2025.

TNXP is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($3.54B) has a higher market cap than TNXP($303M). PTGX has higher P/E ratio than TNXP: PTGX (77.92) vs TNXP (0.01). PTGX YTD gains are higher at: 48.912 vs. TNXP (15.161). PTGX has higher annual earnings (EBITDA): 26.8M vs. TNXP (-75.85M). PTGX has more cash in the bank: 570M vs. TNXP (125M). TNXP has less debt than PTGX: TNXP (492K) vs PTGX (11.3M). PTGX has higher revenues than TNXP: PTGX (209M) vs TNXP (9.83M).
PTGXTNXPPTGX / TNXP
Capitalization3.54B303M1,168%
EBITDA26.8M-75.85M-35%
Gain YTD48.91215.161323%
P/E Ratio77.920.01520,493%
Revenue209M9.83M2,126%
Total Cash570M125M456%
Total Debt11.3M492K2,297%
FUNDAMENTALS RATINGS
PTGX vs TNXP: Fundamental Ratings
PTGX
TNXP
OUTLOOK RATING
1..100
2653
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
46100
SMR RATING
1..100
6398
PRICE GROWTH RATING
1..100
4136
P/E GROWTH RATING
1..100
399
SEASONALITY SCORE
1..100
8519

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TNXP's Valuation (28) in the Pharmaceuticals Other industry is somewhat better than the same rating for PTGX (78) in the Biotechnology industry. This means that TNXP’s stock grew somewhat faster than PTGX’s over the last 12 months.

PTGX's Profit vs Risk Rating (46) in the Biotechnology industry is somewhat better than the same rating for TNXP (100) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew somewhat faster than TNXP’s over the last 12 months.

PTGX's SMR Rating (63) in the Biotechnology industry is somewhat better than the same rating for TNXP (98) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew somewhat faster than TNXP’s over the last 12 months.

TNXP's Price Growth Rating (36) in the Pharmaceuticals Other industry is in the same range as PTGX (41) in the Biotechnology industry. This means that TNXP’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for TNXP (99) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew significantly faster than TNXP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTGXTNXP
RSI
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
70%
Bullish Trend 4 days ago
79%
Momentum
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
78%
Bullish Trend 13 days ago
80%
Declines
ODDS (%)
Bearish Trend 5 days ago
77%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TNXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCVFX34.101.17
+3.55%
Fidelity Advisor Value C
RBCGX75.911.31
+1.76%
Reynolds Blue Chip Growth
LSWWX26.600.40
+1.53%
Loomis Sayles Global Allocation Y
PTMAX22.910.33
+1.46%
PGIM Quant Solutions Large-Cap Cor Eq A
FNIAX47.190.65
+1.40%
Fidelity Advisor New Insights A

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been closely correlated with BIESF. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if PTGX jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+2.57%
BIESF - PTGX
66%
Closely correlated
N/A
MLYS - PTGX
52%
Loosely correlated
+1.88%
TRVI - PTGX
42%
Loosely correlated
+0.80%
DNLI - PTGX
41%
Loosely correlated
+1.71%
ORMP - PTGX
37%
Loosely correlated
+3.88%
More

TNXP and

Correlation & Price change

A.I.dvisor indicates that over the last year, TNXP has been closely correlated with ICU. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if TNXP jumps, then ICU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TNXP
1D Price
Change %
TNXP100%
+5.94%
ICU - TNXP
77%
Closely correlated
N/A
NEVPF - TNXP
41%
Loosely correlated
N/A
TOVX - TNXP
35%
Loosely correlated
-0.23%
CRVS - TNXP
32%
Poorly correlated
+4.91%
IPHA - TNXP
28%
Poorly correlated
+0.90%
More